Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Researchers from Tampere University, Finland, and Izmir Institute of ...

Researchers from Tampere University, Finland, and Izmir Institute of Technology, Turkey, have developed an in vitro cancer model to investigate why breast cancer spreads to bone. Their findings hold ...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis).RK-33 was previously ...

The evolving landscape of musculoskeletal interventional oncology treatment for the management of painful bone metastases.

Patients with breast cancer and bone metastasis have limited treatment options and often rely on palliative care to ease difficult symptoms, including frailty and pain. In most cases, breast ...

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Breast cancer is a significant global public health challenge, with 2.3 ...

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Breast cancer is a significant global public health challenge, with 2.3 million ...

Breast cancer can spread to your bones, lungs, liver, and brain, among other parts of your body. In a 2020 study of 414,528 people with breast cancer, 5,185 people (1.25%) developed metastatic ...

In commemoration of Breast Cancer Awareness Month this October, the POST highlights the journey of survivors and the ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...